• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Finance

Everimmune raises €5m to enter clinical phase in microbiome immuno-oncology

November 30, 2021 Microbiome Times

EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than €5 million (approx. $6M) in a Series A funding from […]

Editor's Choice

Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives

November 23, 2021 Aaron B Cowley and Nicole O'Brien

Live biotherapeutic products (LBPs) are defined by the U.S. FDA as biological products that contain live organisms applicable to the prevention, treatment, or cure of a disease or condition (1). LBP therapies continue to attract […]

Pharma & Human Health

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

November 19, 2021 Microbiome Times

Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, announced positive results from a Phase 1 study of orally-administered NOV-001 in healthy volunteers. The Phase 1 study demonstrated the ability […]

Biotech Showcase

Engineering the Microbiome to Treat Skin Diseases

November 16, 2021 Travis Whitfill

  The skin microbiome plays a fundamental role in human health, protecting against pathogens and antigens, while bolstering cutaneous immunity. Imbalances in the skin microbiome (i.e. “dysbiosis”) are highly associated with severity of skin disease, […]

Pharma & Human Health

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

November 12, 2021 Microbiome Times

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced positive topline results […]

Finance

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

November 10, 2021 Microbiome Times

SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate […]

Finance

ADM to Acquire Deerland Probiotics & Enzymes

November 5, 2021 Microbiome Times

ADM (NYSE: ADM), a global leader in nutrition and agricultural origination and processing, announced a significant expansion of its broad portfolio of health and wellness products and solutions with an agreement to purchase U.S.-based Deerland […]

Pharma & Human Health

Probiotics : A Helping Hand Toward a Fitter Life

October 27, 2021 Microbiome Times

For a long time, consumers have associated metabolic health with a healthy weight, but it goes far beyond that. Metabolic health is not about looking good, it is about being healthy, and it involves having […]

Pharma & Human Health

New study characterizes the gut virome

October 25, 2021 Microbiome Times

A new study has added numerous previously uncharacterized viral genomes and genes to the ever-increasing worldwide pool of human gut viromes. The study, published in mSystems, an open-access journal of the American Society for Microbiology, […]

Pharma & Human Health

Solarea Bio Announces Licensing Agreement with ADM

October 20, 2021 Microbiome Times

Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, announced it has signed a technology licensing agreement with global nutrition leader ADM (NYSE: ADM). Solarea Bio has developed […]

Finance

Axial Therapeutics Raises $37.25 Million in Series C Financing

October 13, 2021 Microbiome Times

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing. OneVentures, a venture capital firm headquartered in Sydney, […]

Posts navigation

« 1 … 31 32 33 … 84 »

Sign Up to Free Newsletter

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter